India’s pharmaceutical sector is preparing for a potential surge in medicine prices as escalating tensions in West Asia disrupt global energy markets and shipping routes critical to drug manufacturing.

Industry experts say medicine and related product prices in India could increase by 10–20% toward the end of March, driven by rising fuel costs, expensive raw materials and mounting logistical disruptions linked to instability around the Strait of Hormuz.

The narrow waterway is one of the world’s most crucial trade corridors for crude oil and cargo shipments. Disruptions in the region are now rippling across supply chains, affecting everything from pharmaceutical ingredients to packaging materials.

Oil shock raises manufacturing costs

The crisis has coincided with sharp fluctuations in global oil prices. Benchmark crude briefly eased after comments from Donald Trump hinted at possible de-escalation, but prices soon climbed again, hovering near $100 per barrel.

For pharmaceutical manufacturers, higher fuel prices translate directly into higher production costs.

A large portion of Active Pharmaceutical Ingredients (APIs) and chemical inputs depend on petroleum-based derivatives. Rising crude prices, therefore, push up the cost of solvents, industrial chemicals, and other materials essential to drug manufacturing.

India imports a significant share of these ingredients from Europe and the Gulf region. Many shipments move through the Strait of Hormuz before reaching Indian ports, making the sector vulnerable to disruptions in the corridor.

Packaging, transport costs surge

The impact is not limited to raw materials. Industry stakeholders say rising energy prices are affecting multiple stages of the pharmaceutical supply chain.

Plastic packaging used for bottles, blister packs and containers is becoming costlier due to expensive petrochemical inputs. Meanwhile, industrial gases required for manufacturing processes are also seeing supply constraints.

Transport is another major pressure point.

Fuel rationing concerns and rising diesel, LPG and CNG prices are increasing the cost of moving medicines from factories to wholesalers and pharmacies.

Freight rates and insurance costs for shipments have also surged as shipping companies reroute vessels or factor in higher geopolitical risks.

Supply chains facing “pandemic-like shock”

Some analysts compare the disruption to supply chain shocks seen during the pandemic. Market observers warn the industry is facing simultaneous pressure on three fronts: rising prices of energy-linked inputs, uncertainty over fuel availability, and disruption of global logistics networks.

These combined stresses could push manufacturers to revise prices or reduce production if the situation persists.

Exports also under pressure

India is the world’s second-largest exporter of pharmaceutical products, supplying affordable medicines to markets across the Gulf, Africa and the United States. Many Indian drugs are approved by the U.S. Food and Drug Administration and exported widely.

However, disruptions in Hormuz have complicated shipments to regional trade hubs such as Dubai and Oman, while deliveries to several African markets are also experiencing delays.

Longer shipping routes and higher insurance premiums are raising costs for exporters, adding to the overall financial pressure on the industry.

Buffer stocks provide short-term relief

For now, the pharmaceutical sector still has some breathing room. Industry bodies say manufacturers typically maintain buffer inventories lasting around three months, which should help cushion immediate shortages.

However, if disruptions continue beyond that period, companies may have to ration supplies or scale back production, a scenario that could push prices higher across pharmacies and hospitals.

Experts say the real impact on medicine prices and availability in India will likely become clearer toward the end of March, when existing inventories begin to thin out.

Until stability returns to the Strait of Hormuz, stakeholders warn the pharma sector may continue to face rising costs and supply uncertainties, developments that could eventually be felt by consumers across the country.